HTV-X1 is set to be released by Canadarm2 from the ISS, remaining in orbit for three months while conducting JAXA-controlled science experiments and technology demonstrations.

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS ...

A cornucopia of coffee destinations recommended by our caffeine connoisseur serves up more than your average cup ...